Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Biomarker-Guided Mycophenolate Mofetil Elimination in Low-Risk Older Adult Kidney Transplant Recipients (OPTIMA-KT)

4. november 2026 oppdatert av: Virginia Commonwealth University

Optimizing Immunosuppression in Low-Risk Older Adult Kidney Transplant Recipients (OPTIMA-KT): A Prospective, Randomized, Open-Label, Blinded-Endpoint Single-Site Pilot/Feasibility Trial of Biomarker-Guided Mycophenolate Mofetil Elimination

Most kidney transplant recipients take a combination of anti-rejection medicines for the rest of their life. One of these is called mycophenolate mofetil (MMF), also known by the brand name CellCept. While MMF helps protect the kidney, taking it for many years can cause infections, low blood counts, stomach problems, and a higher risk of certain cancers, problems that older adults are especially likely to experience.

We are doing this study to learn whether carefully and slowly stopping MMF in older adults who are doing well after their transplant is as safe as continuing MMF, when we use blood and urine tests to closely watch for any early signs of trouble. The information learned could help future kidney transplant patients use less medicine without losing their transplant.

Studieoversikt

Detaljert beskrivelse

To evaluate the feasibility, safety, protocol adherence, biomarker monitoring completion, and preliminary clinical event rates associated with stepwise MMF elimination over 6 months compared with standard-of-care immunosuppression in low-risk older adult kidney transplant recipients.

Secondary objectives. To compare between arms: eGFR trajectory and proteinuria at Months 6 and 12; infection incidence (including CMV and BK), hospitalization, and adverse drug events; de novo DSA incidence and time to de novo DSA; and the kinetics and predictive performance of dd-cfDNA and urine CXCL9 and CXCL10 for rejection and de novo DSA.

Exploratory objectives. To assess the association between PIRCHE-II score and individual primary endpoint components; the performance of combined biomarker panels versus single biomarkers; health-related quality of life and patient-reported outcomes through Month 12; and cost and healthcare resource utilization through Month 12 across study arms.

Studietype

Intervensjonell

Registrering (Antatt)

20

Fase

  • Tidlig fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Virginia
      • Richmond, Virginia, Forente stater, 23298
        • Virginia Commonwealth University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Amber Paulus, PhD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

60 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Greater than 60 years of age
  • Greater than 12 months from kidney transplant
  • Stable maintenance tacrolimus- based immunosuppression for at least 3 months without dose changes greater than 25%
  • PIRCHE-II score less than or equal to 65 calculated from available donor and recipient HLA typing
  • Ability to provide written informed consent and comply with study procedures

Exclusion Criteria:

  • Multi-organ transplant or prior graft loss due to rejection
  • Maintenance immunosuppression including belatacept, cyclosporine, azathioprine, sirolimus, or other agents in lieu of tacrolimus or MMF
  • Steroid-free regimen
  • Active malignancy (excluding non-melanoma skin cancer)
  • Uncontrolled infection
  • BK viremia greater than 10,000 copies/mL, or BK nephropathy
  • High immunologic risk (any preformed DSA, positive crossmatch, or biopsy-proven rejection within the prior 6 months)
  • Pregnancy, breastfeeding, self-reported pregnancy, positive pregnancy test during screening if testing is indicated, or inability/unwillingness to comply with required pregnancy prevention measures if of childbearing potential
  • Inability to comply with study procedures including monthly visits and biospecimen collection
  • Concurrent participation in another conflicting interventional trial.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Standard of Care

Participants continue tacrolimus-based maintenance immunosuppression (tacrolimus, MMF, with or without prednisone)

Administration of Tacrolimus

Participants are administered MMF

Participants in SOC arm may be administered Prednisone as indicated

Eksperimentell: MMF Elimination (Mycophenolate Mofetil )

Mycophenolate Mofetil (MMF) is reduced to approximately 50% of baseline daily dose at Month 1, approximately 25% at Month 2, and discontinued at Month 3, remaining discontinued through Month 6 unless biomarker triggers prompt reinstatement. Tacrolimus trough is maintained at 5 to 8 ng/mL with monthly monitoring and coefficient of variation tracking; prednisone is continued at site-standard dose unless contraindicated.

Administration of Tacrolimus

Participants are administered MMF

Participants in the MMF Elimination arm may be administered prednisone as indicated

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Feasibility of MMF Elimination
Tidsramme: 6 months

Proportion of eligible participants enrolled and retained through completion of the intervention

6 months
Protocol Adherence
Tidsramme: 6 months

Proportion of participants completing the assigned treatment strategy without major protocol deviations

6 months
Biomarker Monitoring Completion
Tidsramme: 6 months

Proportion of scheduled biomarker assessments successfully completed.

6 months
Clinical Composite Event Rate
Tidsramme: 6 months

Time to first occurrence of all-cause death, graft loss, biopsy-proven rejection, major infection requiring IV therapy or hospitalization, graft-related hospitalization, or confirmed de novo donor-specific antibody.

6 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Compare estimated glomerular filtration rate (eGFR) trajectory at Months 6 and 12
Tidsramme: Months 6 and 12

Compare estimated glomerular filtration rate (eGFR) trajectory at Months 6 and 12.

Months 6 and 12
Compare Urine Protein-to-Creatinine Ratio (UPCR) Between Arms at Months 6 and 12
Tidsramme: Months 6 and 12

Compare Urine Protein-to-Creatinine Ratio (UPCR) Between Arms at Months 6 and 12.

Months 6 and 12
Comparison of Infection incidence
Tidsramme: Months 6 and 12

Number of participants experiencing one or more infections

Months 6 and 12
Comparison of Participants Hospitalized
Tidsramme: Months 6 and 12

Number of participants experiencing one or more hospitalizations

Months 6 and 12
Comparison of Total Hospitalizations
Tidsramme: Months 6 and 12

Total number of hospitalizations across all participants

Months 6 and 12
Comparison of adverse events
Tidsramme: Months 6 and 12

Number of participants experiencing one or more adverse events

Months 6 and 12
Comparison of serious adverse events
Tidsramme: Months 6 and 12

Number of participants experiencing one or more serious adverse events

Months 6 and 12
De Novo Donor-Specific Antibody Incidence
Tidsramme: Month 12

Number of participants who develop confirmed de novo donor-specific antibodies after randomization

Month 12
Time to De Novo Donor-Specific Antibody
Tidsramme: Month12

Time from randomization to first confirmed de novo donor-specific antibody

Month12
Donor-Derived Cell-Free DNA (dd-cfDNA)
Tidsramme: Month 12

Longitudinal change in dd-cfDNA and its predictive performance for rejection and de novo donor-specific antibody

Month 12
Urine CXCL9 Concentration (pg/mL)
Tidsramme: Month 12

Longitudinal change in urine CXCL9 and its predictive performance for rejection and de novo donor-specific antibody

Month 12
Urine CXCL10 Concentration (pg/mL)
Tidsramme: Month 12

Longitudinal change in urine CXCL10 and its predictive performance for rejection and de novo donor-specific antibody

Month 12

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Amber Paulus, PhD, Virginia Commonwealth University

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. desember 2026

Primær fullføring (Antatt)

1. februar 2029

Studiet fullført (Antatt)

1. august 2029

Datoer for studieregistrering

Først innsendt

18. august 2026

Først innsendt som oppfylte QC-kriteriene

31. august 2026

Først lagt ut (Faktiske)

8. september 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

4. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Deidentified individual participant data supporting the published results will be available beginning after publication of the primary results and for 10 years after study completion. Access will require investigator approval, IRB approval when applicable, and a data use agreement

IPD-delingstidsramme

10 years after study completion

Tilgangskriterier for IPD-deling

Access will require investigator approval, IRB approval when applicable, and a data use agreement

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • ICF

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere